Yu-Jih Su1,2, Tien-Hsing Chen2,3, Chung-Yuan Hsu1,2, Wen-Tsen Chiu1,2, Yu-Sheng Lin2,4, Ching-Chi Chi2,5. 1. Division of Rheumatology, Allergy, and Immunology, Department of Internal Medicine, Chang Gung Memorial Hospital, Kaohsiung, Taiwan. 2. College of Medicine, Chang Gung University, Taoyuan, Taiwan. 3. Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital, Keelung, Taiwan. 4. Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chiayi, Taiwan. 5. Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan.
Abstract
CONTEXT: The safety of metformin usage by diabetic psoriasis patients is unclear. OBJECTIVE: To investigate the real-world safety of metformin in psoriatic patients with type 2 diabetes mellitus (T2DM). DESIGN: We used the National Health Insurance Research Database to perform a cohort study. Based on metformin and other antidiabetic agent prescriptions, we divided all psoriasis patients with T2DM into the metformin group and the nonmetformin group. The outcomes included all-cause mortality, severe psoriasis, hospitalization due to psoriasis, and any cause for readmission. RESULTS: The metformin group (n = 5520) and the nonmetformin group (n = 3062) did not significantly differ in the risk of all-cause mortality [hazard ratio (HR) 1.08; 95% CI, 0.90 to 1.30], severe psoriasis (HR, 0.95; 95% CI, 0.80 to 1.09), psoriasis-related admission (HR, 1.32; 95% CI, 0.90 to 1.93), and any-cause readmission (HR, 0.99; 95% CI, 0.90 to 1.11). The dose-response analysis found no significant increase in the risk of severe psoriasis and psoriasis-related admission, even with more than 80 defined daily doses or 1000 mg daily dose of metformin prescribed (P for linear trend > 0.05). CONCLUSION: Metformin can be prescribed for diabetic psoriasis patients without safety concerns.
CONTEXT: The safety of metformin usage by diabetic psoriasispatients is unclear. OBJECTIVE: To investigate the real-world safety of metformin in psoriaticpatients with type 2 diabetes mellitus (T2DM). DESIGN: We used the National Health Insurance Research Database to perform a cohort study. Based on metformin and other antidiabetic agent prescriptions, we divided all psoriasispatients with T2DM into the metformin group and the nonmetformin group. The outcomes included all-cause mortality, severe psoriasis, hospitalization due to psoriasis, and any cause for readmission. RESULTS: The metformin group (n = 5520) and the nonmetformin group (n = 3062) did not significantly differ in the risk of all-cause mortality [hazard ratio (HR) 1.08; 95% CI, 0.90 to 1.30], severe psoriasis (HR, 0.95; 95% CI, 0.80 to 1.09), psoriasis-related admission (HR, 1.32; 95% CI, 0.90 to 1.93), and any-cause readmission (HR, 0.99; 95% CI, 0.90 to 1.11). The dose-response analysis found no significant increase in the risk of severe psoriasis and psoriasis-related admission, even with more than 80 defined daily doses or 1000 mg daily dose of metformin prescribed (P for linear trend > 0.05). CONCLUSION:Metformin can be prescribed for diabetic psoriasispatients without safety concerns.
Authors: Alfred A Chan; Houmin Li; Wendy Li; Kathy Pan; Jennifer K Yee; Rowan T Chlebowski; Delphine J Lee Journal: Arch Dermatol Res Date: 2021-11-24 Impact factor: 3.033